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Background: Aspirin is chemopreventive but has signiﬁcant side
effects. We developed NOSH-aspirin a safer, nitric oxide and
hydrogen sulﬁde releasing hybrid.
Aim: Here we report on NOSH-aspirin as an anti-inﬂammatory
and its effects on human cancer cell kinetics and various cancer
xenografts.
Methods: Anti-inﬂammatory: Carageenan rat paw edema model.
Cancer cell lines: Colon, HT-29, HCT 15, SW 480; breast, MCF-7,
MDA-MB-231; pancreas, MIA PaCa2, BxPC3. Normal cell lines:
human mammary, HMEpC; pancreatic epithelial, ACBRI 515. Xeno-
grafts: nude mice implanted with HT-29, MDA-MB-231, MIA PaCa2
cells, were treated with NOSH-aspirin (100 mg/kg/d) or vehicle.
After 3 weeks, mice were sacriﬁced, tumors excised, weighed, and
ﬁxed for IHC studies.
Results: NOSH-aspirin signiﬁcantly reduced paw edema as func-
tion of time. NOSH-aspirin’s IC50 in nM at 24 h for cell growth
inhibition ranged from 50±2 to 250±10 in the cancer cell lines and
about 400-fold higher in the normal cell lines. The cell growth
inhibitory effects were due to a dose-dependent induction of
apoptosis and cell cycle arrest (G0/G1), leading to reductions in
cell proliferation. In xenografts, NOSH-aspirin had no effect on the
weight of the mice. Tumor volume was reduced as a function of
treatment time. At sacriﬁce, tumor mass reductions were colon:
89%, P¼0.005; breast: 91%, P¼0.006; pancreas: 75%, P¼0.0031.
Growth inhibition was due to reduced proliferation (decreased
PCNA expression), and induction of apoptosis (increased TUNEL
positive cells).
Conclusions: NOSH-aspirin is a potent anti-inﬂammatory, prefer-
entially affecting cancer cells and targets parameters important in
determining cellular mass.
http://dx.doi.org/10.1016/j.redox.2015.09.030
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Background: Despite signiﬁcant improvements in the conven-
tional anti-ovarian cancer therapies, tumor cell resistance to
various cytostatic drugs remains a relevant problem. Therefore,
the new cancer treatment strategies are being developed. Among
many agents that have been studied for their potential anti-cancer
activity, the most promising are the nitric oxide (NO) donors-
syntethic compounds that release NO in vivo and/or in vitro.
Aim: We have evaluated the effect of NO donors on the SK-OV-3
and OVCAR-3 ovarian cancer cell lines. We assessed some of the
cancer cells’ speciﬁc features: the uncontrolled proliferation, over-
activation of particular signaling proteins, high resistance to
therapeutics and elevated expression and secretion of invasive-
ness/metastatic factors.
Methods: Two members of NONOates family were used: SPER/NO
and DETA/NO. Cancer cell lines were cultured with different
concentrations of NO donors. The cytotoxic, pro-apoptotic activity
of NO donors and their impact on the phosphorylation status of
STAT-3 and AKT in cells were determined. The expression of VEGF-
A, MMPs and TGF-β was also evaluated.
Results: NO donors inhibited ovarian cancer cells growth making
them also more susceptible to the cisplatin cytotoxic activity. More-
over, both NO donors induced apoptosis of cells and decreased activity
of signaling proteins (STAT3 and AKT). Similarly, SPER/NO and DETA/
NO lowered the secretion of pro-metastatic factors, responsible for
cancer cells invasiveness.
Conclusions: The obtained results show that both NO donors
demonstrated a wide range of action on both ovarian cancer cell
lines. Therefore, they have a high potential of being a supporting
compounds in the cancer therapies.
http://dx.doi.org/10.1016/j.redox.2015.09.031
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Hepatocellular carcinoma develops in cirrhotic liver. The nitric
oxide (NO) synthase type III (NOS-3) overexpression induces cell
death in hepatoma cells. The study developed gene therapy
designed to speciﬁcally overexpress NOS-3 in cultured hepatoma
cells, and in tumors derived from orthotopically implanted tumor
cells in ﬁbrotic livers. Liver ﬁbrosis was induced by CCl4 admin-
istration in mice. Hepa 1-6 cells were used for in vitro and in vivo
experiments. The ﬁrst generation adenovirus was designed to
overexpress NOS-3 (or GFP) and luciferase cDNA under the
regulation of murine alpha-fetoprotein (AFP) and Rous Sarcoma
Virus (RSV) promoters, respectively. Both adenoviruses were
administered through the tail vein two weeks after orthotopic
tumor cell implantation. AFP-NOS-3/RSV-Luciferase increased
oxidative-related DNA damage, p53, CD95/CD95L expression and
caspase-8 activity in cultured Hepa 1-6 cells. The increased
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